391 related articles for article (PubMed ID: 9884079)
1. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP.
Liu H; Maurice DH
Br J Pharmacol; 1998 Dec; 125(7):1501-10. PubMed ID: 9884079
[TBL] [Abstract][Full Text] [Related]
2. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
Rose RJ; Liu H; Palmer D; Maurice DH
Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
[TBL] [Abstract][Full Text] [Related]
3. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
Maurice DH
Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
[TBL] [Abstract][Full Text] [Related]
4. Expression of cyclic nucleotide phosphodiesterase 3A in isolated rat submandibular acini.
Shimizu K; Murata T; Hiramoto K; Sugiyama T; Nakagawa T; Manganiello VC; Tagawa T
Arch Oral Biol; 2006 Feb; 51(2):83-8. PubMed ID: 16102722
[TBL] [Abstract][Full Text] [Related]
5. Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues.
Palmer D; Maurice DH
Mol Pharmacol; 2000 Aug; 58(2):247-52. PubMed ID: 10908291
[TBL] [Abstract][Full Text] [Related]
6. Differential function of the alpha2A-adrenoceptor and Phosphodiesterase-3B in human adipocytes of different origin.
Dicker A; Kaaman M; van Harmelen V; Aström G; Blanc KL; Rydén M
Int J Obes (Lond); 2005 Dec; 29(12):1413-21. PubMed ID: 16077714
[TBL] [Abstract][Full Text] [Related]
7. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.
Sun B; Li H; Shakur Y; Hensley J; Hockman S; Kambayashi J; Manganiello VC; Liu Y
Cell Signal; 2007 Aug; 19(8):1765-71. PubMed ID: 17482796
[TBL] [Abstract][Full Text] [Related]
8. Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo.
Tilley DG; Maurice DH
Mol Pharmacol; 2002 Sep; 62(3):497-506. PubMed ID: 12181425
[TBL] [Abstract][Full Text] [Related]
9. Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues.
Dunkerley HA; Tilley DG; Palmer D; Liu H; Jimmo SL; Maurice DH
Mol Pharmacol; 2002 May; 61(5):1033-40. PubMed ID: 11961121
[TBL] [Abstract][Full Text] [Related]
10. New insight into the role of phosphodiesterase 3A in porcine oocyte maturation.
Sasseville M; Côté N; Guillemette C; Richard FJ
BMC Dev Biol; 2006 Oct; 6():47. PubMed ID: 17038172
[TBL] [Abstract][Full Text] [Related]
11. Cardiac type cGMP-inhibited phosphodiesterase (PDE3A) gene structure: similarity and difference to adipocyte type PDE3B gene.
Kasuya J; Liang SJ; Goko H; Park SH; Kato K; Xu ZD; Hockman S; Manganiello VC; Fujita-Yamaguchi Y
Biochem Biophys Res Commun; 2000 Feb; 268(3):827-34. PubMed ID: 10679291
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 3 and 5 and cyclic nucleotide-gated ion channel expression in rat trigeminovascular system.
Kruse LS; Sandholdt NT; Gammeltoft S; Olesen J; Kruuse C
Neurosci Lett; 2006 Aug; 404(1-2):202-7. PubMed ID: 16808996
[TBL] [Abstract][Full Text] [Related]
13. Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells.
Aizawa T; Wei H; Miano JM; Abe J; Berk BC; Yan C
Circ Res; 2003 Sep; 93(5):406-13. PubMed ID: 12919948
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F; MacLean MR; Pyne NJ
Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
[TBL] [Abstract][Full Text] [Related]
15. Effects of a phosphodiesterase 3 inhibitor, olprinone, on rhythmical change in tension of human gastroepiploic artery.
Adachi H; Kakiki M; Kishi Y
Eur J Pharmacol; 2005 Dec; 528(1-3):137-43. PubMed ID: 16325808
[TBL] [Abstract][Full Text] [Related]
16. Characterization of phosphodiesterase 3 in human malignant melanoma cell line.
Murata T; Shimizu K; Narita M; Manganiello VC; Tagawa T
Anticancer Res; 2002; 22(6A):3171-4. PubMed ID: 12530061
[TBL] [Abstract][Full Text] [Related]
17. PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle.
Murthy KS; Zhou H; Makhlouf GM
Am J Physiol Cell Physiol; 2002 Mar; 282(3):C508-17. PubMed ID: 11832336
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide-induced changes in endothelial expression of phosphodiesterases 2, 3, and 5.
Schankin CJ; Kruse LS; Reinisch VM; Jungmann S; Kristensen JC; Grau S; Ferrari U; Sinicina I; Goldbrunner R; Straube A; Kruuse C
Headache; 2010 Mar; 50(3):431-41. PubMed ID: 19751368
[TBL] [Abstract][Full Text] [Related]
19. Plasma membrane cyclic nucleotide phosphodiesterase 3B (PDE3B) is associated with caveolae in primary adipocytes.
Nilsson R; Ahmad F; Swärd K; Andersson U; Weston M; Manganiello V; Degerman E
Cell Signal; 2006 Oct; 18(10):1713-21. PubMed ID: 16503395
[TBL] [Abstract][Full Text] [Related]
20. Cyclic nucleotide PDE-3. Quantitation of PDE-3A and -3B mRNAs in rat tissues by RNase protection assay.
Nagaoka T; Shirakawa T; Kasuya J; Balon TW; Manganiello VC; Fujita-Yamaguchi Y
Cell Biochem Biophys; 1998; 29(1-2):49-66. PubMed ID: 9631238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
